# Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarterial Chemoembolization Combined With or Without Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

> **NCT07109336** · NA · NOT_YET_RECRUITING · sponsor: **Zhongda Hospital** · enrollment: 790 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma

## Interventions

- **DEVICE:** Heterogeneous Treatment Effect-Based Decision Model

## Key facts

- **NCT ID:** NCT07109336
- **Lead sponsor:** Zhongda Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 790 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07109336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07109336, "Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarterial Chemoembolization Combined With or Without Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07109336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*